SI3003327T1 - Polimeri, ki vežejo protone, za peroralno dajanje - Google Patents
Polimeri, ki vežejo protone, za peroralno dajanje Download PDFInfo
- Publication number
- SI3003327T1 SI3003327T1 SI201430466T SI201430466T SI3003327T1 SI 3003327 T1 SI3003327 T1 SI 3003327T1 SI 201430466 T SI201430466 T SI 201430466T SI 201430466 T SI201430466 T SI 201430466T SI 3003327 T1 SI3003327 T1 SI 3003327T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical composition
- use according
- independently hydrogen
- formula
- hydrogen
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 39
- 150000001412 amines Chemical class 0.000 claims abstract 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract 4
- 210000002966 serum Anatomy 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000001257 hydrogen Substances 0.000 claims 33
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 22
- 125000001931 aliphatic group Chemical group 0.000 claims 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 6
- 208000010444 Acidosis Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 206010027417 Metabolic acidosis Diseases 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims 3
- 229940085991 phosphate ion Drugs 0.000 claims 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 2
- 239000008367 deionised water Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000010526 radical polymerization reaction Methods 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Claims (30)
- EP 3003327 BI Polimeri, ki vežejo protone, za peroralno dajanje Patentni zahtevki1. Farmacevtski sestavek za uporabo pri postopku zdravljenja metabolične acidoze s peroralnim dajanjem farmacevtskega sestavka, kjer sestavek obsega premrežen aminski polimer, ki veže protone in ki obsega ostanek amina, ki ustreza formuli 1:Formula 1 kjer: Ri, R2 in R3 so neodvisno vodik, hidrokarbil, substituiran hidrokarbil, vendar pod pogojem, daje vsaj eden od Ri, R2 in R3 drugačen od vodika, premreženi aminski polimer ima ravnotežno razmerje nabrekanja v deionizirani vodi 5 ali manj; premreženi aminski polimer veže kloridne ione proti interferirajočim ionom v molskem razmerju vsaj 0,35 : 1 v interferirajočem ionskem pufru pri 37 °C, kjer so interferirajoči ioni fosfatni ioni in je interferirajoči ionski pufer pufrana raztopina 36 mM klorida in 20 mM fosfata in ima pH 5,5.
- 2. Farmacevtski sestavek za uporabo po zahtevku 1, kjer ima premreženi aminski polimer ravnotežno razmerje nabrekanja v deionizirani vodi 4 ali manj, ali 3 ali manj, ali 2 ali manj, ali 1,5 ali manj, ali 1 ali manj.
- 3. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer so Ri, R2 in R3 neodvisno vodik, alkil, alkenil, alil, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, etrski del, heteroaril ali heterociklična skupina, vendar pod pogojem, da ni vsak od R(, R2 in R3 vodik, ali bolj podrobno, farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer so Rt, R2 in R3 neodvisno vodik, alifat ali heteroalifat, vendar pod pogojem, daje vsaj eden od Ri, R2 in R3 drugačen od vodika.
- 4. Farmacevtski sestavek za uporabo po katerem koli od zahtevkov 1-3, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli la, in je premreženi aminski polimer pripravljen z radikalsko polimerizacijo amina, ki ustreza formuli la:Formula 1a kjer sta R4 in R5 neodvisno vodik, hidrokarbil ali substituiran hidrokarbil.
- 5. Farmacevtski sestavek za uporabo po zahtevku 4, kjer sta R4 in R5 neodvisno vodik, alkil, alkenil, alil, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, etrski del, heteroaril ali heterociklična skupina, ali bolj podrobno, farmacevtski sestavek po zahtevku 4, kjer sta R4 in R5 neodvisno vodik, alifat ali heteroalifat.
- 6. Farmacevtski sestavek za uporabo po katerem koli od zahtevkov 1-3, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli lb, in je premreženi aminski polimer pripravljen s substitucijsko polimerizacijo amina, ki ustreza formuli lb, s polifunkcionalnim premreževalnim sredstvom:Fromula 1b kjer sta R4 in R5 neodvisno vodik, hidrokarbil ali substituiran hidrokarbil, je alifat in R<5i ter R$2 sta neodvisno vodik, alifat ali heteroalifat.
- 7. Farmacevtski sestavek za uporabo po zahtevku 6, kjer sta R4 in R5 neodvisno vodik, nasičen ogljikovodik, nenasičen alifat, aril, heteroaril, heteroalkil ali nenasičen heteroalifat, ali bolj podrobno, farmacevtski sestavek po zahtevku 6, kjer sta R» in R5 neodvisno vodik, alkil, alkenil, alil, vinil, aril, aminoalkil, alkanol, haloalkil, hidroksialkil, etrski del, heteroaril ali heterociklična skupina, ali bolj podrobno, farmacevtski sestavek po zahtevku 6, kjer sta R4 in R5 neodvisno vodik, alil ali aminoalkil.
- 8. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli lc:Formula 1c kjer je R7 vodik, alifat ali heteroalifat in je Rg alifat ali heteroalifat.
- 9. Farmacevtski sestavek za uporabo po katerem koli od zahtevkov 1-3, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli 2:Formula 2 kjer: m in n sta neodvisno celi števili, ki nista negativni; Rio, R20» R30 in R40 so neodvisno vodik, hidrokarbil ali substituiran hidrokarbil; Xije:X2 je hidrokarbil ali substituiran hidrokarbil; vsak Xn je neodvisno vodik, hidrokarbil, substituiran hidrokarbil, hidroksi ali amino; in z je število, ki ni negativno.
- 10. Farmacevtski sestavek za uporabo po zahtevku 9, kjer so Ri0, R2o, R30 in R»o neodvisno vodik, alifat, aril, heteroalifat ali heteroaril, m in z sta neodvisno 0-3 in nje 0 ali 1, in/ali kjer je X2 alifat ali heteroalifat.
- 11. Farmacevtski sestavek za uporabo po zahtevku 9 ali 10, kjer je m enak 1-3 in je Xn vodik, alifat ali heteroalifat.
- 12. Farmacevtski sestavek za uporabo po katerem koli od zahtevkov 1-3, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli 2a:Formula 2a kjer: m in n sta neodvisno celi števili, ki nista negativni; vsak R11 je neodvisno vodik, hidrokarbil, heteroalifat ali heteroaril; Rži in R3i sta neodvisno vodik ali heteroalifat; R41 je vodik, substituiran hidrokarbil ali hidrokarbil; Xije:X2 je alkil ali substituiran hidrokarbil; vsak X12 je neodvisno vodik, hidroksi, amino, aminoalkil, boronska kislina ali halo; in z je število, ki ni negativno.
- 13. Farmacevtski sestavek za uporabo po zahtevku 12, kjer sta m in z neodvisno 0-3 in je n enak 0 ali 1.
- 14. Farmacevtski sestavek za uporabo po zahtevku 12 ali 13, kjer je Rn neodvisno vodik, alifat, aminoalkil, haloalkil ali heteroaril, R21 in R3J sta neodvisno vodik ali heteroalifat in R» je vodik, alifat, aril, heteroalifat ali heteroaril, ali bolj podrobno, farmacevtski sestavek po zahtevku 12 ali 13, kjer je vsak Rn vodik, alifat, aminoalkil ali haloalkil, R2j in R3i sta vodik ali aminoalkil in R^ je vodik, alifat ali heteroalifat.
- 15. Farmacevtski sestavek za uporabo po katerem koli od zahtevkov 1-3, kjer premreženi aminski polimer obsega ostanek amina, ki ustreza formuli 2b:Formula 2b kjer: m in n sta neodvisno celi števili, ki nista negativni; vsak Ruje neodvisno vodik, substituiran hidrokarbil ali hidrokarbil; R22 in R32 sta neodvisno vodik, substituiran hidrokarbil ali hidrokarbil; R42 je vodik, hidrokarbil ali substituiran hidrokarbil; Xije:X2 je alkil, aminoalkil ali alkanol; vsak Χ13 je neodvisno vodik, hidroksi, aliciklična skupina, amino, aminoalkil, halogen, alkil, heteroaril, boronska kislina ali aril; z je število, ki ni negativno; in amin, ki ustreza formuli 2b, obsega vsaj eno alilno skupino.
- 16. Farmacevtski sestavek za uporabo po zahtevku 15, kjer sta m in z neodvisno 0-3 in je n enak 0 ali 1.
- 17. Farmacevtski sestavek za uporabo po zahtevku 15 ali 16, kjer R)2 ali R»2 neodvisno obsega vsaj en alilni ali vinilni del, ali farmacevtski sestavek po zahtevku 15 ali 16, kjer je (i) m pozitivno celo število in R12, R22 in R42 v kombinaciji obsegajo vsaj dva alilna ali vinilna dela ali je (ii) n pozitivno celo število in Ri2, R32 in R42 v kombinaciji obsegajo vsaj dva alilna ali vinilna dela.
- 18. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer ima premreženi aminski polimer vezavno molsko razmerje kloridnega iona proti fosfatnemu ionu vsaj 0,5 : 1 v vodnem simuliranem tankočrevesnem anorganskem pufru ("SIB"), ki vsebuje 36 mM NaCl, 20 mM NaH2P04 in 50 mM 2-(N-morfolino)etansulfonske kisline (MES) in je pufran na pH 5,5 ter pri 37 °C.
- 19. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer ima premreženi aminski polimer vezavno molsko razmerje kloridnega iona proti fosfatnemu ionu vsaj 1 : 1 v vodnem simuliranem tankočrevesnem anorganskem pufru ("SIB"), ki vsebuje 36 mM NaCl, 20 mM NaH2P04 in 50 mM 2-(N- morfolino)etansulfonske kisline (MES) in je pufran na pH 5,5 ter pri 37 °C.
- 20. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer ima premreženi aminski polimer vezavno molsko razmerje kloridnega iona proti fosfatnemu ionu vsaj 2 : 1 v vodnem simuliranem tankočrevesnem anorganskem pufru ("SIB"), ki vsebuje 36 mM NaCl, 20 mM NaH2P04 in 50 mM 2-(N- morfolino)etansulfonske kisline (MES) in je pufran na pH 5,5 ter pri 37 °C.
- 21. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer ima premreženi aminski polimer vezavno kapaciteto za protone vsaj 10 mmol/g in vezavno kapaciteto za kloridne ione vsaj 10 mmol/g v vodnem simuliranem gastričnem tekočinskem pufru ("SGF"), ki vsebuje 35 mM NaCl in 63 mM HC1 pri pH 1,2 in 37 °C.
- 22. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer ima premreženi aminski polimer ravnotežno vezavno kapaciteto za protone vsaj 12 mmol/g in vezavno kapaciteto za kloridne ione vsaj 12 mmol/g, ali ravnotežno vezavno kapaciteto za protone vsaj 14 mmol/g in vezavno kapaciteto za kloridne ione vsaj 14 mmol/g v vodnem simuliranem gastričnem tekočinskem pufru ("SGF"), ki vsebuje 35 mM NaCl in 63 mM HC1 pri pH 1,2 in 37 °C.
- 23. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer je vezava klorida pri preizkusu SIB po enourni izpostavitvi polimera preizkusnemu pufru pri 37 °C večja od 2,0 mmol na gram polimera, ali večja od 2,5 mmol/g polimera, ali večja od 3,0 mmol/g polimera, ali večja od 3,5 mmol/g polimera, ali večja od 4,0 mmol/g polimera.
- 24. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer se da manj kot 1 g, 0,5 g ali 0,1 g natrija ali kalija na dan, ali kjer se ne da nobenega natrija ali kalija.
- 25. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer je dnevni odmerek, ki se ga da, manj kot 20 g, ali manj kot 15 g, ali manj kot 10 g, ali manj kot 5 g, ali manj kot 4 g, ali manj kot 3 g.
- 26. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer se da dnevni odmerek enkrat na dan, ali dvakrat na dan, ali trikrat na dan.
- 27. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer je metabolična acidoza kronična metabolična acidoza.
- 28. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer dnevni odmerek vodi do podaljšanega povečanja serumskega bikarbonata v miliekvivalentih na liter: > 1,6, ali > 2, ali > 3, ali > 5, ali >10.
- 29. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer se pri postopku odmerek titrira na osnovi vrednosti serumskega bikarbonata pacienta, ki potrebuje zdravljenje, ali drugih indikatorjev acidoze.
- 30. Farmacevtski sestavek za uporabo po katerem koli prejšnjem zahtevku, kjer je metabolična acidoza označena z vrednostjo serumskega bikarbonata manj kot 22 miliekvivalentov na liter.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361831445P | 2013-06-05 | 2013-06-05 | |
EP14742001.2A EP3003327B1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
PCT/US2014/041152 WO2014197725A1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3003327T1 true SI3003327T1 (sl) | 2018-01-31 |
Family
ID=51212941
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201430466T SI3003327T1 (sl) | 2013-06-05 | 2014-06-05 | Polimeri, ki vežejo protone, za peroralno dajanje |
SI201431698T SI3578185T1 (sl) | 2013-06-05 | 2014-06-05 | Polimeri, ki vežejo protone za oralno administracijo |
SI201431241T SI3287133T1 (sl) | 2013-06-05 | 2014-06-05 | Polimeri, ki vežejo protone,za peroralno dajanje |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431698T SI3578185T1 (sl) | 2013-06-05 | 2014-06-05 | Polimeri, ki vežejo protone za oralno administracijo |
SI201431241T SI3287133T1 (sl) | 2013-06-05 | 2014-06-05 | Polimeri, ki vežejo protone,za peroralno dajanje |
Country Status (25)
Country | Link |
---|---|
US (8) | US9205107B2 (sl) |
EP (4) | EP3287133B1 (sl) |
JP (4) | JP6453860B2 (sl) |
KR (4) | KR102318910B1 (sl) |
CN (3) | CN111671766B (sl) |
AU (3) | AU2014274817B2 (sl) |
BR (1) | BR112015030142B1 (sl) |
CA (1) | CA2912911C (sl) |
CY (3) | CY1119611T1 (sl) |
DK (3) | DK3003327T3 (sl) |
ES (3) | ES2646271T3 (sl) |
HK (3) | HK1222120A1 (sl) |
HR (3) | HRP20171590T1 (sl) |
HU (3) | HUE034836T2 (sl) |
IL (3) | IL242758B (sl) |
LT (3) | LT3003327T (sl) |
MX (3) | MX364785B (sl) |
NO (1) | NO2905572T3 (sl) |
PL (2) | PL3287133T3 (sl) |
PT (3) | PT3578185T (sl) |
RS (2) | RS59033B1 (sl) |
RU (1) | RU2728778C2 (sl) |
SI (3) | SI3003327T1 (sl) |
TR (1) | TR201909355T4 (sl) |
WO (1) | WO2014197725A1 (sl) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3003327T (lt) | 2013-06-05 | 2017-12-27 | Tricida Inc. | Protonus surišantys polimerai, skirti geriamajam vartojimui |
ES2857177T3 (es) * | 2014-12-10 | 2021-09-28 | Tricida Inc | Polímeros de unión de protones para administración oral |
US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
WO2018124264A1 (ja) | 2016-12-28 | 2018-07-05 | 富士フイルム株式会社 | 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法 |
US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
EP3698799B1 (en) | 2017-10-16 | 2022-01-26 | FUJIFILM Corporation | Hyperphosphatemia treatment agent |
US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019090177A1 (en) * | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Method of treating acid-base disorders |
MA51628A (fr) * | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
CN114450364A (zh) * | 2019-07-19 | 2022-05-06 | 阿卡特肖勒公司 | 分子上定义明确的抗生物污损和聚离子涂层 |
EP4053179A1 (en) | 2021-03-01 | 2022-09-07 | Tricida Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
WO2023109825A1 (zh) * | 2021-12-14 | 2023-06-22 | 上海石趣医药科技有限公司 | 氧化银和/或其水合物在制备药物中的用途 |
CN115260355A (zh) * | 2022-05-16 | 2022-11-01 | 江苏中天药业有限公司 | 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂 |
KR20230047972A (ko) | 2023-03-21 | 2023-04-10 | 최문수 | 개인별 맞춤형 그립 형상이 형성된 운동기구용 손잡이 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US5534259A (en) * | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
AU703842B2 (en) | 1994-10-17 | 1999-04-01 | Robert M. Bersin | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders |
US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
CA2317549C (en) * | 1998-01-05 | 2006-04-11 | University Of Washington | Composition for enhancing transport through lipid-containing membranes, and uses thereof |
WO1999040990A1 (en) | 1998-02-17 | 1999-08-19 | University Of Maryland | Anion binding polymers and the use thereof |
US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
WO2001066607A1 (fr) | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant |
AU2001241076A1 (en) | 2000-03-09 | 2001-09-17 | Hisamitsu Pharmaceutical Co. Inc. | Crosslinked anion-exchange resin or salt thereof |
WO2001068106A1 (fr) | 2000-03-13 | 2001-09-20 | Hisamitsu Pharmaceutical Co., Inc. | Prophylactiques et/ou remedes pour hyperphosphatemie |
JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
AU2002252632B2 (en) * | 2001-04-18 | 2004-09-23 | Genzyme Corporation | Low salt forms of polyallylamine |
CA2444347A1 (en) | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Method for treating gout and binding uric acid |
US20050234129A1 (en) | 2002-03-11 | 2005-10-20 | Sutton Paul A | Salts of nateglinide |
WO2004069866A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
CN1540136A (zh) * | 2003-10-27 | 2004-10-27 | 华东理工大学 | 一种评价微生物驱油能力的方法 |
US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
WO2005065291A2 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
CA2553931A1 (en) | 2004-01-29 | 2005-08-11 | Keio University | Erythrocyte function modifying substance |
US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
EP1732523B9 (en) | 2004-03-30 | 2010-06-02 | Relypsa, Inc. | Potassium binding polymers and uses thereof |
US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
NZ552706A (en) | 2004-07-19 | 2011-01-28 | Nutricia Nv | Use of aspartate for regulating glucose levels in blood |
DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
ES2342947T3 (es) * | 2004-10-13 | 2010-07-19 | Ilypsa, Inc. | Polimeros de amina reticulados. |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
WO2006078629A2 (en) * | 2005-01-18 | 2006-07-27 | Duke University | In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair |
WO2007004236A2 (en) | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
MX2008002360A (es) | 2005-08-18 | 2008-04-29 | Globoasia Llc | Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos. |
JP2009507019A (ja) | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
CA2624170C (en) * | 2005-09-30 | 2014-02-25 | Ilypsa, Inc. | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
GB2446076B (en) | 2005-09-30 | 2010-11-24 | Ilypsa Inc | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
CN102600202A (zh) | 2005-11-08 | 2012-07-25 | 味之素株式会社 | 麻醉苏醒促进剂 |
AR060690A1 (es) | 2005-11-08 | 2008-07-10 | Genzyme Corp | Polimeros que contienen magnesio para la hiperfosfatemia |
ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
RU2008136081A (ru) | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
US20080085259A1 (en) | 2006-05-05 | 2008-04-10 | Huval Chad C | Amine condensation polymers as phosphate sequestrants |
EP2043627A2 (en) | 2006-07-05 | 2009-04-08 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
CN101541235A (zh) * | 2006-07-18 | 2009-09-23 | 基酶有限公司 | 胺类树状物 |
EP2049014A2 (en) * | 2006-07-18 | 2009-04-22 | Genzyme Corporation | Amine dendrimers |
US8391873B2 (en) | 2006-07-21 | 2013-03-05 | Qualcomm Incorporated | Systems and methods for coordinating supplementary services for voice telephone calls in a centralized fashion |
US20090325860A1 (en) | 2006-08-04 | 2009-12-31 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
US8187634B2 (en) | 2006-09-01 | 2012-05-29 | Usv, Ltd. | Process for the preparation of sevelamer hydrochloride and formulation thereof |
BRPI0716066A2 (pt) * | 2006-09-01 | 2013-09-17 | Genzyme Corp | composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina |
JP5427029B2 (ja) | 2006-09-06 | 2014-02-26 | スキャンポ・アーゲー | 消化管の重炭酸分泌を促進するための方法および組成物 |
EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
BRPI0720234A2 (pt) | 2006-12-14 | 2013-12-24 | Genzyme Corp | Composição farmacêutica |
EP2114376A1 (en) | 2007-02-23 | 2009-11-11 | Genzyme Corporation | Amine polymer compositions |
US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
JP2010520285A (ja) | 2007-03-08 | 2010-06-10 | ゲンズイメ コーポレーション | スルホンポリマー組成物 |
TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
US20100166696A1 (en) | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
WO2009005838A2 (en) | 2007-07-02 | 2009-01-08 | Cognate3 Llc | Process for the preparation of a non-corrosive base solution and methods of using same |
US20100189679A1 (en) * | 2007-07-11 | 2010-07-29 | Toray Industries, Inc. | Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes |
EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
US20090181359A1 (en) * | 2007-10-25 | 2009-07-16 | Lou Sheng C | Method of performing ultra-sensitive immunoassays |
US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
US20100316589A1 (en) | 2007-12-14 | 2010-12-16 | Hitesh Bhagat | Coated Pharmaceutical Compositions |
PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
AU2009223063A1 (en) | 2008-03-11 | 2009-09-17 | Livionex Inc. | Methods and compositions for treating inflammation and inflammation-related pathologies |
RU2010145166A (ru) | 2008-04-08 | 2012-05-20 | Юсв Лимитед (In) | Способ получения соли аминополимера |
CN102014843B (zh) | 2008-04-11 | 2013-06-19 | Gp合资有限公司 | 用于人体组织的超声处理的机头 |
US20110142952A1 (en) | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US20100104527A1 (en) | 2008-08-22 | 2010-04-29 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
CN102223790B (zh) | 2008-09-25 | 2015-11-25 | 维乌作物保护有限公司 | 生产聚合物纳米颗粒的方法和活性成分的制剂 |
WO2010035273A2 (en) | 2008-09-29 | 2010-04-01 | Intec Pharma Ltd. | Novel gastroretentive delivery system |
WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
EP2389168A2 (en) | 2009-01-22 | 2011-11-30 | USV Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
CN102917699A (zh) | 2009-10-13 | 2013-02-06 | 密执安大学评议会 | 树枝状聚合物组合物和合成方法 |
EP2490675B1 (en) | 2009-10-22 | 2019-01-23 | Synthon B.V. | Pharmaceutical compositions of sevelamer |
WO2011071927A2 (en) | 2009-12-07 | 2011-06-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
AU2011220742B2 (en) | 2010-02-24 | 2016-02-25 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
CN107266681A (zh) * | 2010-02-24 | 2017-10-20 | 瑞立普萨公司 | 用作胆汁酸螯合剂的胺聚合物 |
EP2538947B1 (en) * | 2010-02-24 | 2016-08-17 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
RU2417782C1 (ru) * | 2010-03-03 | 2011-05-10 | Федеральное государственное образовательное учреждение высшего профессионального образования "Белгородская государственная сельскохозяйственная академия" | Способ лечения ацидоза рубца |
IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
WO2012021648A1 (en) * | 2010-08-10 | 2012-02-16 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
KR102150135B1 (ko) | 2012-06-21 | 2020-08-31 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 만성 신장 질환 환자의 치료에서 시트르산 제2철의 용도 |
KR20210005314A (ko) | 2012-10-08 | 2021-01-13 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
LT3003327T (lt) | 2013-06-05 | 2017-12-27 | Tricida Inc. | Protonus surišantys polimerai, skirti geriamajam vartojimui |
EP3747432A1 (en) | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
ES2857177T3 (es) | 2014-12-10 | 2021-09-28 | Tricida Inc | Polímeros de unión de protones para administración oral |
US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
WO2019090177A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Method of treating acid-base disorders |
US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
MA51628A (fr) | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
-
2014
- 2014-06-05 LT LTEP14742001.2T patent/LT3003327T/lt unknown
- 2014-06-05 TR TR2019/09355T patent/TR201909355T4/tr unknown
- 2014-06-05 SI SI201430466T patent/SI3003327T1/sl unknown
- 2014-06-05 PT PT191692599T patent/PT3578185T/pt unknown
- 2014-06-05 LT LTEP19169259.9T patent/LT3578185T/lt unknown
- 2014-06-05 WO PCT/US2014/041152 patent/WO2014197725A1/en active Application Filing
- 2014-06-05 PL PL17177221T patent/PL3287133T3/pl unknown
- 2014-06-05 PT PT147420012T patent/PT3003327T/pt unknown
- 2014-06-05 KR KR1020157036999A patent/KR102318910B1/ko active IP Right Grant
- 2014-06-05 KR KR1020237024806A patent/KR102633597B1/ko active IP Right Grant
- 2014-06-05 SI SI201431698T patent/SI3578185T1/sl unknown
- 2014-06-05 EP EP17177221.3A patent/EP3287133B1/en active Active
- 2014-06-05 ES ES14742001.2T patent/ES2646271T3/es active Active
- 2014-06-05 JP JP2016518006A patent/JP6453860B2/ja active Active
- 2014-06-05 PL PL14742001T patent/PL3003327T3/pl unknown
- 2014-06-05 ES ES17177221T patent/ES2733493T3/es active Active
- 2014-06-05 CN CN202010780603.3A patent/CN111671766B/zh active Active
- 2014-06-05 BR BR112015030142-8A patent/BR112015030142B1/pt active IP Right Grant
- 2014-06-05 AU AU2014274817A patent/AU2014274817B2/en active Active
- 2014-06-05 DK DK14742001.2T patent/DK3003327T3/en active
- 2014-06-05 EP EP19169259.9A patent/EP3578185B1/en active Active
- 2014-06-05 KR KR1020247003745A patent/KR20240023672A/ko active Search and Examination
- 2014-06-05 HU HUE14742001A patent/HUE034836T2/en unknown
- 2014-06-05 CA CA2912911A patent/CA2912911C/en active Active
- 2014-06-05 CN CN201480032395.1A patent/CN105377270B/zh active Active
- 2014-06-05 SI SI201431241T patent/SI3287133T1/sl unknown
- 2014-06-05 RS RS20190806A patent/RS59033B1/sr unknown
- 2014-06-05 KR KR1020217034420A patent/KR20210131457A/ko not_active Application Discontinuation
- 2014-06-05 DK DK19169259.9T patent/DK3578185T3/da active
- 2014-06-05 EP EP14742001.2A patent/EP3003327B1/en active Active
- 2014-06-05 MX MX2015016527A patent/MX364785B/es active IP Right Grant
- 2014-06-05 EP EP20183421.5A patent/EP3812761A1/en active Pending
- 2014-06-05 HU HUE19169259A patent/HUE051198T2/hu unknown
- 2014-06-05 RS RS20201307A patent/RS61005B1/sr unknown
- 2014-06-05 LT LTEP17177221.3T patent/LT3287133T/lt unknown
- 2014-06-05 HU HUE17177221A patent/HUE043999T2/hu unknown
- 2014-06-05 ES ES19169259T patent/ES2834485T3/es active Active
- 2014-06-05 PT PT17177221T patent/PT3287133T/pt unknown
- 2014-06-05 CN CN202010780604.8A patent/CN111671767B/zh active Active
- 2014-06-05 DK DK17177221.3T patent/DK3287133T3/da active
- 2014-06-05 RU RU2015155596A patent/RU2728778C2/ru active
- 2014-06-23 US US14/311,852 patent/US9205107B2/en active Active
-
2015
- 2015-01-27 NO NO15000230A patent/NO2905572T3/no unknown
- 2015-11-18 US US14/944,844 patent/US9925214B2/en active Active
- 2015-11-24 IL IL242758A patent/IL242758B/en active IP Right Grant
- 2015-12-01 MX MX2021013880A patent/MX2021013880A/es unknown
- 2015-12-01 MX MX2019005300A patent/MX2019005300A/es unknown
-
2016
- 2016-08-30 HK HK16110308.8A patent/HK1222120A1/zh unknown
- 2016-10-05 HK HK16111588.7A patent/HK1223288A1/zh unknown
-
2017
- 2017-09-26 US US15/715,934 patent/US9993500B2/en active Active
- 2017-10-18 HR HRP20171590TT patent/HRP20171590T1/hr unknown
- 2017-11-06 CY CY20171101159T patent/CY1119611T1/el unknown
-
2018
- 2018-06-07 US US16/002,306 patent/US10391118B2/en active Active
- 2018-06-07 US US16/002,269 patent/US10363268B2/en active Active
- 2018-08-16 HK HK18110550.1A patent/HK1251151B/zh unknown
- 2018-12-13 JP JP2018233254A patent/JP6759316B2/ja active Active
-
2019
- 2019-04-04 US US16/375,843 patent/US10369169B1/en active Active
- 2019-06-14 HR HRP20191074TT patent/HRP20191074T1/hr unknown
- 2019-07-04 CY CY20191100694T patent/CY1121801T1/el unknown
- 2019-08-16 US US16/542,969 patent/US11197887B2/en active Active
- 2019-08-22 AU AU2019219800A patent/AU2019219800B1/en active Active
- 2019-12-04 AU AU2019275584A patent/AU2019275584B2/en active Active
-
2020
- 2020-01-09 IL IL271932A patent/IL271932B/en active IP Right Grant
- 2020-09-02 JP JP2020147224A patent/JP7075455B2/ja active Active
- 2020-10-20 IL IL278183A patent/IL278183B/en unknown
- 2020-10-30 CY CY20201101028T patent/CY1123673T1/el unknown
- 2020-11-02 HR HRP20201767TT patent/HRP20201767T1/hr unknown
-
2021
- 2021-12-09 US US17/546,339 patent/US20220096534A1/en active Pending
-
2022
- 2022-05-13 JP JP2022079329A patent/JP2022107004A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3003327T1 (sl) | Polimeri, ki vežejo protone, za peroralno dajanje | |
MX2020001734A (es) | Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7). | |
CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
CY1122648T1 (el) | Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη | |
TR201905009T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. | |
AR061838A1 (es) | Moduladores de propiedades farmacocineticas de terapeuticos | |
JP2015512413A5 (sl) | ||
RU2020100459A (ru) | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии | |
JP2016512426A5 (sl) | ||
CA2750413A1 (en) | Hydroxamic acid derivatives | |
JP2013542992A5 (sl) | ||
BRPI0517916B8 (pt) | comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido | |
RU2014139169A (ru) | Парентеральные составы для введения макролидных антибиотиков | |
JP2016520652A5 (sl) | ||
BR112021019007A2 (pt) | Protacs que degradam o receptor de estrogênio | |
WO2016094685A1 (en) | Proton-binding polymers for oral administration | |
JP2020520893A5 (sl) | ||
RU2015143165A (ru) | Производные маннозы для лечения бактериальных инфекций | |
MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. | |
JOP20210319A1 (ar) | مركبات بيروليدين | |
RU2010151143A (ru) | Замещенные хиназолины | |
JP2015528509A5 (sl) | ||
RU2014128528A (ru) | Лечение диабета I и II типа | |
RU2011127128A (ru) | Лечение гломерулонефрита | |
RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно |